ArticleMedComm2026
Loss of Rab8a-Dependent Tethering of Lipid Droplets to Mitochondria Contributes to Hypoxia-Reoxygenation Injury.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tethering of lipid droplets (LDs) to mitochondria facilitates fatty acid oxidation and is a key adaptive response that helps cardiomyocytes cope with hypoxia-reoxygenation (HR) stress. However, the molecular mechanisms regulating these interactions during ischemia are not fully understood. We found that HR significantly decreased cardiomyocyte expression and phosphorylation of Rab8a, a small GTPase that interacts with the LD-associated protein perilipin 5 to mediate LD-mitochondria tethering. Using long-chain fatty acid (LCFA) tracking assays we confirmed that loss of Rab8a disrupted physical contact between these organelles to impair the transfer of LCFA from LDs to mitochondria. Furthermore, HR led to the accumulation of intracellular lipids via a combination of both lipolysis and lipophagy, resulting in metabolic stress. To counteract this defect, we evaluated the therapeutic potential of ALY688, a peptide agonist of adiponectin receptors known to stimulate the AMPK-Rab8a signaling axis. Our data indicated that treatment with ALY688 preserved Rab8a expression during HR, thereby maintaining LD-mitochondria interactions and improving metabolic function. These findings uncover a novel Rab8a-dependent mechanism regulating lipid metabolism under ischemic/hypoxic stress and highlight the potential of adiponectin mimetics like ALY688 to mitigate metabolic dysfunction in ischemic heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.